Full-Time

Associate – Roivant Health

Confirmed live in the last 24 hours

Roivant Sciences

Roivant Sciences

201-500 employees

Develops biopharmaceuticals and RNA therapeutics

Biotechnology
Healthcare

Compensation Overview

$115k - $150kAnnually

+ Bonus + Equity

Entry

New York, NY, USA

Category
Bioinformatics
Computational Biology
Genomics
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Data Science
Requirements
  • Outstanding educational background
  • Desire to operate in a highly entrepreneurial environment—you will have full ownership and high-accountability for your own ideas and work
  • Intellectual curiosity and comfort with significant ambiguity—you build expertise in many challenging but high-opportunity spaces across healthcare technology
  • Ability to wear multiple hats and execute at a high-velocity—you will be able to participate in all aspects of company building
  • Executive-level communication and analytical skills—you will be collaborating with executives, investors, and key partners frequently
  • Specialized knowledge in one or more of the following areas:
  • Healthcare technology
  • Medicine and/or life sciences
  • Data science, advanced statistical techniques (ML, etc.), or related product experience
  • Experience building new ventures, whether in an incubation / investor setting, at a startup, or within larger organization
Responsibilities
  • Participating in early-stage ideation by mapping ideas to a variety of qualifying factors, including time to market, sources of Roivant advantage, validation path, market size, etc.
  • Developing and driving workplans for evaluating early-stage concepts, and leading evaluation of markets, competitors, and other key factors with quantitative and qualitative analyses
  • Supporting the initial stages of company building, including early business development, zero-to-one product development, business operations, and fundraising
  • Developing the recruiting workplan and profile archetypes to help execute the recruitment of the CEO and other key leaders
  • Supporting incubated opportunities by working directly with their leadership team on critical analyses at key inflection points of the business (e.g., fundraising)

Roivant Sciences develops and delivers medicines and technologies aimed at improving patient health, focusing on drug candidates for genetic disorders and RNA therapeutics. The company operates by maximizing the potential of these candidates through a combination of in-house development and strategic partnerships, which helps build a strong pipeline of drugs. One of its key subsidiaries, Genevant, specializes in RNA therapeutics, utilizing proprietary delivery platforms for mRNA, RNAi, and gene editing to create effective treatments for specific diseases. Roivant generates revenue through drug development, licensing agreements, and partnerships, with the goal of bringing innovative treatments to market efficiently.

Company Stage

IPO

Total Funding

$1.8B

Headquarters

New York City, New York

Founded

2014

Growth & Insights
Headcount

6 month growth

0%

1 year growth

1%

2 year growth

-11%
Simplify Jobs

Simplify's Take

What believers are saying

  • Roivant's recent $7.1B deal with Roche to acquire Telavant highlights its strong potential for lucrative partnerships and significant financial growth.
  • The company's diverse pipeline, including promising RNA therapeutics and gene editing technologies, offers substantial opportunities for breakthrough treatments.
  • Strategic investments, such as the $2.02 million from Exchange Traded Concepts LLC, indicate strong investor confidence and financial stability.

What critics are saying

  • The failure of the lupus drug brepocitinib in Phase 2 trials underscores the inherent risks in drug development and potential setbacks.
  • Rumors of acquiring Immunovant, Inc. could lead to financial strain and integration challenges if not managed properly.

What makes Roivant Sciences unique

  • Roivant Sciences leverages a unique business model that combines in-house product development with strategic partnerships, setting it apart from traditional biopharmaceutical companies.
  • The company's focus on RNA therapeutics and genetic disorders, particularly through its subsidiary Genevant, positions it at the forefront of cutting-edge medical treatments.
  • Roivant's ability to rapidly advance its drug pipeline and form strategic alliances allows it to bring innovative treatments to market more quickly and efficiently than many competitors.

Help us improve and share your feedback! Did you find this helpful?